ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1355	National Cancer Institute	Html	en	Rectal Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of rectal cancer.	metastatic colorectal carcinoma 0.354846 hepatic colorectal metastases 0.223514 recurrent rectal cancer 0.223407 Engl J Med 0.263348 Ann Surg 0.278325 colorectal cancer risk 0.276481 asymptomatic colorectal cancer 0.241606 colorectal cancer surgery 0.262375 metastatic colorectal cancer 0.610251 adjuvant rectal cancer 0.215149 colorectal cancer 0.902264 randomized trial 0.206269 patients 0.22566 progressive colorectal cancer 0.233252 pT3-pT4 colorectal cancer 0.254826 Clin Cancer Res 0.224834 refractory metastatic colorectal 0.227594 malignant colorectal adenomas 0.207762 et al. 0.485182 familial colorectal cancer 0.266438 colorectal liver metastases 0.255119 measurable colorectal cancer 0.232282 Dis Colon Rectum 0.282416 PUBMED Abstract 0.3294	untreated metastatic colorectal 0.230109 colorectal hepatic metastases 0.221405 advanced colorectal cancer 0.352094 irinotecan-refractory metastatic colorectal 0.231657 Colorectal lung metastases 0.222615 advanced colorectal carcinoma 0.23983 recurrent colorectal cancer 0.262817 Surg Oncol 0.226556 colorectal cancer incidence 0.264939 colorectal cancer present 0.264636 colorectal cancer disparities 0.265307 colorectal cancer group 0.277657 colorectal cancer rates 0.265187 Colorectal Study Group 0.21517 Abstract 0.47664 colon cancer 0.223051 Clin Oncol 0.752938 Colorectal cancer follow-up 0.250811 liver-limited metastatic colorectal 0.225511 Oncol Biol Phys 0.206575 dutch colorectal cancer 0.274376 Clin Colorectal Cancer 0.277838 Cancer J Clin 0.227264 colorectal carcinoma metastases 0.224249	CLICK HERE
1369	National Cancer Institute	Html	en	Oral Cavity and Oropharyngeal Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for oral cancer.	oral examination 0.527557 primary screening tool 0.417249 squamous cell tumors. 0.370971 one-time oral cancer 0.520022 systematic oral cavity 0.508919 United States 0.382344 follow-up period 0.371029 sole randomized trial 0.365707 physical examination 0.446254 cause-specific mortality benefit 0.39145 opportunistic screening 0.371936 control group 0.369767 short follow-up period 0.359545 earlier stage cancers 0.419364 randomized controlled trials 0.375895 oral visual screening 0.601987 simple hand-held device 0.363139 oral cancer mortality 0.59501 premalignant lesions 0.420448 oral visual examination 0.580404 premalignant oral lesions. 0.561468 statistically significant result 0.355967 toluidine blue staining 0.36957 direct fluorescence visualization 0.371807	blue placebo dye. 0.359062 oral cancer 0.97737 oral/pharyngeal cancers 0.364948 oral surgery 0.457512 oral cancers 0.781555 15-year follow-up period 0.369337 overall annual incidence 0.409124 overall oral cancers 0.566597 routine examination 0.355451 screening group 0.361703 subclinical high-risk fields 0.375561 oral cancer examination. 0.562099 positive predictive values 0.349612 mortality hazard ratios 0.399552 population-based screening programs 0.456558 better health outcomes. 0.355075 oral cavity 0.532106 positive test rates 0.356123 periodic health examination 0.447578 oral cancer examination 0.728118 screening setting 0.362271 screening rounds 0.355833 cause–specific mortality rate 0.408751	CLICK HERE
1770	National Cancer Institute	Html	es	Prurito (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del prurito (picazón en la piel) como complicación del cáncer o su tratamiento. Se consideran los abordajes de manejo y tratamiento del prurito.	haemodialysis patients 0.476654 Section XII 0.477073 Rubenstein E 0.559292 Sin embargo 0.803552 Scientific American Medicine 0.676981 categoría farmacológica medicamento 0.526417 Am Acad Dermatol 0.571569 Clin Res 0.479277 Wolff K 0.536775 Acad Dermatol Venereol 0.493209 Farber EM 0.55456 patients with atopic 0.550773 Cancer Nursing 0.471101 PDQ Prurito 0.665745 Dermatol Venereol Leprol 0.6251 with atopic dermatitis 0.566467 toxina botulínica 0.473345 reacciones cutáneas 0.538217 patients with 0.621762 chronic idiopathic 0.533598 Pain Symptom Manage 0.649291 neuropathic pruritus 0.513717 Scientific American 0.875762 Oncol Nurs Forum 0.782558 Malignant cutaneous tumors 0.546882	Dosis Comentarios Referencias 0.53479 General Medicine 0.52531 terminal cancer patient 0.535978 All Free Clear 0.515267 Dermatol Venereol 0.632286 farmacológica medicamento dosis 0.550466 Clinical aspects 0.477546 Medicamento Dosis Comentarios 0.541353 Acta Derm Venereol 0.979711 Eisen AZ 0.543793 New York 0.832579 patients receiving 0.483634 Yosipovitch G 0.516371 mg diarios comenzar 0.507465 Abel EA 0.553787 Enterostomal Ther 0.474722 sistema nervioso central 0.522009 pruritus relief with 0.489446 policitemia vera 0.673444 Dermatol Ther 0.602936 Fitzpatrick TB 0.546636 Federman DD 0.567864 Bernhard JD 0.556935 chronic pruritus 0.522206	CLICK HERE
1843	National Cancer Institute	Html	es	Tratamiento del cáncer de vesícula biliar (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vesícula biliar.	gemcitabina vs 0.562266 Compton CC 0.670359 Tsukada K 0.846255 Surg Oncol Clin 0.680412 situ carcinoma 0.687891 accessed october 0.566163 Trimodality therapy 0.564056 American Cancer Society 0.950284 7th ed 0.669585 Estadio II–IV 0.581785 Chijiiwa K 0.675106 Surgical indications 0.564187 Instituto Nacional 0.7169 Primary carcinoma 0.710358 clasificación patológica t2 0.60477 Uchida K 0.58031 enfermedad t2 0.580737 Arch Surg 0.626332 Inapparent carcinoma 0.891598 determinados pacientes 0.681197 fármacos radiosensibilizadores 0.863769 biliary tract 0.652373 radical second operation 0.814041 Expandable metal stents 0.585727 estadio iv 0.572834	Cancer Facts 0.649725 surgical resection 0.561157 Shoup M 0.562495 Am Surg 0.635005 Cancer Staging Manual 0.913061 National Cancer Institute 0.633613 Surg Oncol 0.770159 from carcinoma 0.694816 PDQ Tratamiento 0.671094 New York 0.64622 second operation after 0.820352 tumor dissemination 0.618784 Physician Data Query 0.581575 Radiation therapy 0.568753 ganglios linfáticos n1 0.740227 Yoshida K 0.701223 estadio focal iia 0.6289 Byrd DR 0.659361 after simple cholecystectomy 0.807902 Tis Carcinoma 0.710719 Am Coll Surg 0.657212 T)a aReproducción 0.561453 AJCC Cancer Staging 0.929134 Edge SB 0.670645	CLICK HERE
1884	National Cancer Institute	Html	es	Tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple).	mieloma múltiple grupo 0.317462 multicentre randomized study 0.314956 Rajkumar SV 0.360993 Durie BG 0.317277 Dispenzieri A 0.381536 primary plasma cell 0.32094 Lacy MQ 0.31455 extramedullary plasmacytoma 0.321972 light chain 0.421207 Myeloma Study Group 0.325182 versus deferred treatment 0.314362 plasma cell 0.333759 monoclonal gammopathies 0.324288 Radiat Oncol Biol 0.320101 multiple myeloma 0.968571 systemic amyloidosis 0.315374 stem cell transplantation 0.348134 International Myeloma Working 0.450729 células plasmáticas tipo 0.324338 proteína m 0.360491 Rosiñol L 0.316442 patients with 0.434191 patients with primary 0.318338 plasma cell leukemia 0.319942 UK Myeloma Forum 0.317407	células madre 0.338769 Myeloma Working Group 0.450073 International Blood 0.317358 primary systemic amyloidosis 0.314303 peripheral blood stem 0.321195 células plasmáticas oligosecretoras 0.325603 Therneau TM 0.332031 monoclonal gammopathy 0.501114 Dimopoulos MA 0.326344 Kumar SK 0.315489 lesiones óseas 0.347582 light chain amyloidosis 0.337292 International Staging System 0.324252 monoclonal sérica tipo 0.317411 Kyle RA 0.395277 Clin Oncol 0.474276 myeloma with 0.317498 Oncol Biol Phys 0.320425 mieloma múltiple estadio 0.31799 Nordic Myeloma Study 0.324636 with newly diagnosed 0.31487 células plasmáticas neoplasia 0.324857 mieloma múltiple igg 0.323238 patients with newly 0.318559	CLICK HERE
1912	National Cancer Institute	Html	es	Tratamiento de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles.	síndromes mielodisplásicos.Quimioterapia 0.302945 linfocítica aguda 0.307126 siguientes procedimientos 0.33161 siguientes aspectos 0.303162 Neurofibromatosis tipo 0.303799 células madre formadoras 0.308269 siguientes especialistas 0.302945 hueso compacto 0.308024 neoplasias mieloides 0.310246 célula madre mieloide 0.324347 Bultos indoloros 0.302618 líquido cefalorraquídeo 0.326401 leucemia mielomonocítica 0.41887 Instituto Nacional 0.305639 célula madre linfoide 0.318549 siguientes problemas 0.302781 leucemia mielógena 0.419565 neoplasias mielodisplásicas 0.302899 LMA recién 0.316713 cáncer regrese).El 0.307025 madre mieloides 0.328575 células madre mieloides 0.318746 leucemia promielocítica aguda 0.371662 células madre 0.977959 leucemia mielógena aguda 0.321693	leucemia aguda 0.310888 leucemia linfoblástica aguda 0.335277 síndromes mielodisplásicos 0.43219 enlace drugs approved 0.308769 Acute Myeloid Leukemia 0.309058 infantil recidivante 0.30755 Sudores nocturnos 0.302372 efectos tardíos 0.309904 médula ósea.Leucemia mielógena 0.31318 células cancerosas.El gemtuzumab 0.309349 punción espinal.Ampliar 0.30255 leucemia granulocítica aguda 0.320187 PDQ Tratamiento 0.305949 blastocitos mieloides 0.303489 tirosina cinasa 0.339619 sistema nervioso central 0.381371 leucemia mieloblástica aguda 0.320188 Physician Data Query 0.305829 enfermedades mieloides 0.315553 SMD)Algunos tratamientos 0.302284 revés.La prueba 0.301997 leucemia mieloide aguda 0.981978 célula madre 0.354129 siguientes sumarios 0.305018	CLICK HERE
2070	National Cancer Institute	Html	es	Inhibidores de la angiogénesis	Hoja informativa que describe el proceso de eliminación de suministro de sangre a los tumores. Incluye una lista de los cánceres en los que se está probando este enfoque.	vasos sanguíneos resultantes 0.32417 NCI de estudios 0.304711 llamadas metástasis 0.305878 posibles efectos 0.304824 Drug Administration 0.306756	células renales 0.307581 angiogénesis efectos 0.326284 Estados Unidos 0.315596 vasos sanguíneos 0.986577	CLICK HERE
3605	National Cancer Institute	Html	en	Enhancing Drug Discovery and Development	The discovery and development of new therapeutic agents for cancer is essential for continued progress against the disease. Historically, NCI has played a vital role in cancer drug discovery and development, and, today, that role continues. Frequently, NCI’s drug development efforts focus on unmet needs that are not being adequately addressed by the private sector.	human tumor cell 0.493589 Developmental Therapeutics Program 0.373741 cell lines 0.756764 corresponding cancer types 0.401362 primary cancer cells 0.471158 drug discovery 0.918943 cell line panel 0.382826 long-term cell cultures 0.381121 drug screening 0.363881 development activities 0.393342 human cancer models 0.633791 human tumor samples 0.437784 precision medicine 0.432081 congressionally mandated initiative 0.360908 human cancer cell 0.54738 drug resistance 0.374751 tyrosine kinase inhibitor 0.365397 drug development efforts 0.451048 potential anticancer agents 0.404376 traditional cell lines 0.391913 parental tumors 0.388039 routine cancer care 0.38291 Cancer Treatment 0.353066 cancer cells 0.647891 cancer cell lines 0.473566	new human cancer 0.517038 cancer cell biology 0.425139 NCI Experimental Therapeutics 0.397544 tumor sections 0.354283 cell line screen 0.52167 largest cancer pharmacology 0.402164 cell culture techniques 0.37598 NCI-60 cell line 0.515114 drug discovery program 0.435482 NIH Clinical Center 0.354806 cancer stem cells 0.444759 anticancer drug discovery 0.568944 biologic agent discovery 0.381604 new therapeutic agents 0.383079 Cancer Chemotherapy National 0.425183 NCI’s anticancer 0.350161 clinical development resources 0.397358 NCI’s drug 0.370038 original tumor 0.350461 normal cell counterparts 0.370786 cancer drug discovery 0.678381 Human cancer cells 0.468312 multiple cell types 0.380725 tumor microenvironment 0.401449	CLICK HERE
16680	National Cancer Institute	Html	en	Cancer Moonshot℠ Implementation	Implementation teams are considering multiple ways to fund new programs as well as expansions of ongoing efforts to advance the goals of the Cancer Moonshot.	Cancer Moonshot-related research 0.688251 ongoing efforts 0.579887 funding opportunity announcements 0.69197 authorization 0.517804 oversight 0.515337 Cancer Moonshot portfolio 0.716496 academia 0.515431 Cancer Moonshot goals 0.684682 Century Cures Act 0.85793 expansions 0.51624 implementation teams 0.716347 email Partnerships_CancerMoonshot 0.582993 list 0.516345 Scientific Advisors 0.584259 important role 0.585193 longer-term scientific initiatives 0.700429 research opportunities 0.75591 multiple ways 0.591922 private sector 0.587499 Cancer Moonshot 0.987984 Cancer Moonshot initiatives 0.68956 concept proposals 0.656557 automatic email 0.583279 receipt 0.519207	NCI intramural staff 0.745934 cancer research community 0.682183 NCI extramural program 0.749793 Program Leadership Committee 0.655079 potential partners 0.586537 available FOAs 0.62206 NCI’s Board 0.674346 NIH institutes 0.582819 existing funds 0.59672 new research opportunities 0.683581 21st Century Cures 0.861565 scientific opportunities 0.594628 Blue Ribbon Panel 0.846596 BRP recommendation 0.740701 working groups 0.588634 new funding concepts 0.653803 BRP recommendations 0.654047 Public-private partnerships 0.590589 Cancer Moonshot implementation 0.678145 NCI advisory committees 0.753041 NCI’s Scientific 0.67691 report 0.517155 new programs 0.586358 funding mechanism 0.587953	CLICK HERE
16708	National Cancer Institute	Html	en	ALCHEMIST (The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): Questions and Answers	ALCHEMIST represents three integrated, precision medicine trials that are designed to identify people with early-stage lung cancer who have tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against those mol	certain genetic alterations 0.511031 ALK gene rearrangement 0.86792 specific genetic alterations 0.510493 lung cancer 0.965003 ALK genetic alterations 0.561732 component trials 0.510228 National Clinical Trials 0.497396 clinical trials 0.62346 early-stage lung cancer 0.707269 EGFR gene mutation 0.628828 best treatment approach 0.483241 lung cancers 0.649896 ALK Treatment component 0.564764 ECOG-ACRIN Cancer Research 0.536673 ALK rearrangement 0.515701 non-small cell lung 0.519586 Adjuvant Lung Cancer 0.554841 EGFR gene mutations 0.510846 uncommon genetic changes 0.484048 ALCHEMIST treatment trial 0.613717 new treatment approaches 0.481108 lung carcinoid tumors 0.539366 early-stage lung cancers 0.57159 appropriate ALCHEMIST treatment 0.663904	ALK gene 0.888431 precision medicine trials 0.560161 tumor tissue 0.58358 United States 0.513049 Dana-Farber Cancer Institute 0.495276 ALK alterations 0.531283 small cell lung 0.519071 National Cancer Institute 0.484824 ALCHEMIST study 0.594796 cancer risk characteristics 0.487226 EGFR Treatment component 0.512344 participants 0.568322 ALCHEMIST treatment trials 0.868218 genetic alterations 0.637424 complete surgical removal 0.527484 Cancer Research Group 0.536403 early-stage lung adenocarcinoma 0.54246 cell lung cancer 0.575738 Cancer Genomics 0.482098 FDA-approved Vysis ALK 0.52631 ALCHEMIST screening trial 0.716569 ALCHEMIST trials 0.680442 standard therapy 0.505511 Clinical Trials Agreement 0.491455	CLICK HERE